After hours: 4:19PM EDT
|Bid||6.70 x 300|
|Ask||7.00 x 200|
|Day's Range||6.89 - 7.38|
|52 Week Range||4.10 - 15.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.60|
PHOENIX, April 18, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced plans to advance ...
GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.
An experimental medication that could become the first drug derived from a marijuana plant approved in the U.S. received a boost from Food and Drug Administration staff.
These two biotechs are big losers so far this year. But which has the better shot at being a winner over the long run?
A handful of threats lobbed at opioid-based drugmakers pressured shares of the pain relief specialist following a dismal earnings report.
PHOENIX, April 02, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of ...
PHOENIX, March 19, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement:. ...
People Also Watch
|Symbol||Last Price||Change||% Change|
Cara Therapeutics, Inc.
|12.36||+ 0.02||+ 0.16%|
GW Pharmaceuticals Plc - Americ
|137.01||+ 4.58||+ 3.46%|
Zynerba Pharmaceuticals, Inc.
CANOPY GROWTH CORP
AURORA CANNABIS IN
|Downgrade||PiperJaffray : Neutral to Underweight||3/9/2018|
|Downgrade||PiperJaffray : to Neutral||5/10/2017|
|Initiated||Janney Capital : to Buy||4/14/2016|
|Initiated||Jefferies : to Buy||12/8/2014|
|Downgrade||Oppenheimer : to Perform||11/12/2014|
|Initiated||PiperJaffray : to Overweight||10/29/2014|
Industry : Biotechnology
Full Time Employees : 343
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.